KR20070010161A - 정신분열증 및/또는 당조절 이상 치료방법 - Google Patents

정신분열증 및/또는 당조절 이상 치료방법 Download PDF

Info

Publication number
KR20070010161A
KR20070010161A KR1020067022972A KR20067022972A KR20070010161A KR 20070010161 A KR20070010161 A KR 20070010161A KR 1020067022972 A KR1020067022972 A KR 1020067022972A KR 20067022972 A KR20067022972 A KR 20067022972A KR 20070010161 A KR20070010161 A KR 20070010161A
Authority
KR
South Korea
Prior art keywords
alkyl
hydrogen
formula
compound
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020067022972A
Other languages
English (en)
Korean (ko)
Inventor
크레이크 피 스미스
데이비드 이 렘프
베스 보로우스키
사타파나 콩사무트
Original Assignee
아벤티스 파마슈티칼스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아벤티스 파마슈티칼스 인크. filed Critical 아벤티스 파마슈티칼스 인크.
Publication of KR20070010161A publication Critical patent/KR20070010161A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020067022972A 2004-04-01 2005-04-01 정신분열증 및/또는 당조절 이상 치료방법 Ceased KR20070010161A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55845104P 2004-04-01 2004-04-01
US60/558,451 2004-04-01

Publications (1)

Publication Number Publication Date
KR20070010161A true KR20070010161A (ko) 2007-01-22

Family

ID=34978926

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067022972A Ceased KR20070010161A (ko) 2004-04-01 2005-04-01 정신분열증 및/또는 당조절 이상 치료방법

Country Status (26)

Country Link
US (1) US20070129403A1 (https=)
EP (2) EP1734959B1 (https=)
JP (1) JP2007531730A (https=)
KR (1) KR20070010161A (https=)
CN (1) CN1946399A (https=)
AR (1) AR048197A1 (https=)
AT (1) ATE446754T1 (https=)
AU (1) AU2005231446A1 (https=)
BR (1) BRPI0509512A (https=)
CA (1) CA2561162A1 (https=)
CL (1) CL2009001605A1 (https=)
CY (1) CY1109734T1 (https=)
DE (1) DE602005017373D1 (https=)
DK (1) DK1734959T3 (https=)
DO (1) DOP2005000050A (https=)
ES (1) ES2334241T3 (https=)
GT (1) GT200500063A (https=)
IL (1) IL178168A0 (https=)
MX (1) MXPA06011222A (https=)
PA (1) PA8628601A1 (https=)
PL (1) PL1734959T3 (https=)
PT (1) PT1734959E (https=)
SI (1) SI1734959T1 (https=)
SV (1) SV2006002069A (https=)
TW (1) TW200602040A (https=)
WO (1) WO2005097122A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170017434A (ko) 2015-08-07 2017-02-15 계명대학교 산학협력단 오렉신 a를 함유하는 당뇨병 치료용 약학 조성물

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
MY144968A (en) 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR063280A1 (es) 2006-10-12 2009-01-21 Xenon Pharmaceuticals Inc Uso de compuestos de espiro-oxindol como agentes terapeuticos
JP2010506853A (ja) * 2006-10-12 2010-03-04 ゼノン・ファーマシューティカルズ・インコーポレイテッド 疼痛などのナトリウムチャネル媒介性の疾患の処置のための、スピロ（［３，２−フロ］ピリジン−３，３’−インドール）−２’（１’ｈ）−オン誘導体および関連化合物
CN105218565A (zh) 2008-10-17 2016-01-06 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途
CA2741024A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
WO2010068750A2 (en) * 2008-12-11 2010-06-17 Board Of Trustees Of Leland Stanford Junior University Compositons and method for treatment of mood and cognitive impairments
AU2010256541B2 (en) * 2009-06-03 2016-03-10 Marquette University Modulation of KCNQ potassium channel activity for treatment of psychiatric disorders and the symptoms thereof
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
MX2012004373A (es) 2009-10-14 2012-06-28 Xenon Pharmaceuticals Inc Metodos sinteticos para compuestos espiro-oxoindol.
CA2788440A1 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CN103512972A (zh) * 2013-07-29 2014-01-15 上海交通大学 精神分裂症的生物标志物及其使用方法和应用
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
ES3025836T3 (en) 2016-08-24 2025-06-09 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating functional decline
AU2020242978B2 (en) 2019-03-19 2025-10-02 Cambridge Cognition Limited Method and uses of diagnosing and recommending treatment for a psychotic disorder

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880822A (en) * 1987-04-24 1989-11-14 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyridinyl)-1H-indol-1-amines
US4970218A (en) 1987-04-24 1990-11-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyridinyl)-1H-indol-1-amines
ATE115143T1 (de) * 1987-04-24 1994-12-15 Hoechst Roussel Pharma N-(pyridinyl)-1h-indol-1-amine, verfahren zu deren herstellung und ihre verwendung als arzneimittel.
US5102891A (en) * 1990-07-23 1992-04-07 Hoechst-Roussel Pharmaceuticals Inc. 1-(substituted pyridinylamino)-1H-indol-5-yl substituted carbamates
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
US5356910A (en) * 1993-07-19 1994-10-18 Hoechst-Roussel Pharmaceuticals Inc. Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder
NZ312577A (en) * 1995-07-27 1999-08-30 Hoechst Marion Roussel Inc Use of optionally substituted n-(pyrrol-1-yl)-pyridinamines as anticonvulsant agents
AU727775B2 (en) 1996-01-17 2000-12-21 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
PL338013A1 (en) 1997-07-16 2000-09-25 Novo Nordisk As Derivatives of condensed 1,2,4-thiadiazine, their production and application
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170017434A (ko) 2015-08-07 2017-02-15 계명대학교 산학협력단 오렉신 a를 함유하는 당뇨병 치료용 약학 조성물

Also Published As

Publication number Publication date
IL178168A0 (en) 2006-12-31
GT200500063A (es) 2005-10-14
MXPA06011222A (es) 2007-01-16
CL2009001605A1 (es) 2009-11-27
SV2006002069A (es) 2006-05-24
JP2007531730A (ja) 2007-11-08
AR048197A1 (es) 2006-04-05
EP2138176A1 (en) 2009-12-30
CY1109734T1 (el) 2014-09-10
DE602005017373D1 (de) 2009-12-10
DK1734959T3 (da) 2010-03-08
BRPI0509512A (pt) 2007-09-11
CN1946399A (zh) 2007-04-11
ES2334241T3 (es) 2010-03-08
EP1734959A2 (en) 2006-12-27
PA8628601A1 (es) 2006-05-16
ATE446754T1 (de) 2009-11-15
TW200602040A (en) 2006-01-16
AU2005231446A1 (en) 2005-10-20
PT1734959E (pt) 2009-12-24
DOP2005000050A (es) 2005-11-30
WO2005097122A3 (en) 2006-02-02
PL1734959T3 (pl) 2010-03-31
SI1734959T1 (sl) 2010-02-26
WO2005097122A2 (en) 2005-10-20
US20070129403A1 (en) 2007-06-07
EP1734959B1 (en) 2009-10-28
CA2561162A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
KR20070010161A (ko) 정신분열증 및/또는 당조절 이상 치료방법
TWI519299B (zh) 大麻素與抗精神病藥物組合使用之技術
US12503485B2 (en) Human aminosterol ENT-03 compounds, related compositions comprising the same, and methods of using the same
US20100178277A1 (en) Methods and compositions for stimulating cells
US9345694B2 (en) Compounds for enhancing arginase activity and methods of using same
JP2010116412A (ja) 精神分裂病を治療するための方法および組成物
US20150174107A1 (en) Trkb agonists and methods of use
JP2010504338A (ja) 筋萎縮性側索硬化症（ＡＬＳ）の治療のための水素化ピリド［４，３−ｂ］インドール
EP2185150B1 (en) Use of tranilast and derivatives thereof for the therapy of neurological conditions
US20130123248A1 (en) Pharmacological modulation of positive ampa receptor modulator effects on neurotrophin expression
US20220265646A1 (en) Piezo agonists for preventing or reverting abnormal amyloid deposition
KR20200101948A (ko) 신경계 질환 치료제
AU2019247871A1 (en) Compositions and methods for increasing remyelination
JP2022511266A (ja) 陰性症状および障害を処置するため、神経可塑性を増大するため、ならびに神経保護を促進するためのロルペリドンの使用
ES2948767T3 (es) Moléculas orgánicas pequeñas para uso en el tratamiento de trastornos neuroinflamatorios
PT1658062E (pt) Derivados de alfa-amino amida úteis como agentes antiinflamatórios
JP5974062B2 (ja) 疼痛制御及び脱髄損傷の回復におけるｎ−２−ヒドロキシ−エチル−ピペラジン−ｎ’−２−エタンスルホン酸（ｈｅｐｅｓ）の役割
CN118697754A (zh) 香蒲新苷在制备治疗缺血性脑卒中药物的应用
US6350768B1 (en) Combination of riluzole and of gabapentin and its use as a medicament
US20090221610A1 (en) Compositions and Methods for Treating Cognitive Disorders
WO2026017114A1 (zh) 一种苯基嘧啶酮化合物的用途
RU2508096C2 (ru) Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии
KOTAGAL et al. 5| PARKINSON SYNDROMES: PROGRESSIVE SUPRANUCLEAR PALSY
Bantel Anaesthetic Preconditioning: The Role of ATP-sensitive K+ Channels
UA97540U (uk) Спосіб лікування бічного аміотрофічного склерозу препаратами з матеріалу ембріофетального походження та виділених з нього клітин

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20061101

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20091231

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110706

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20111130

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20110706

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I